Definitive Healthcare price target lowered to $7 from $11 at Barclays

Barclays analyst Saket Kalia lowered the firm’s price target on Definitive Healthcare to $7 from $11 and keeps an Equal Weight rating on the shares. The company reported better than expected billings growth for Q1 which can be attributed to a “cleaner” renewal pool after lapping customers churning and downshifting pricing last year, the analyst tells investors in a research note. However, the firm says new business is slowing.